Suggested remit: To appraise the clinical and cost effectiveness of pacritinib within its marketing authorisation for treating myelofibrosis.
Following on from information provided to NICE by the company in January 2019, the appraisal of Pacritinib for treating myelofibrosis [ID880] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 880
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- CTI BioPharma (pacritinib)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Leukaemia CARE
- MPN Voice
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Bristol-Myers Squibb (hydroxycarbamide)- confidentiality form not signed, not participating
- Celgene (lenalidomide, thalidomide) - confidentiality form not signed, not participating
- Medac UK (hydroxycarbamide) - confidentiality form not signed, not participating
- Nordic (hydroxycarbamide) - confidentiality form not signed, not participating
- Novartis (ruxolitinib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Pacritinib for treating myelofibrosis [ID880] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 February 2019 | Suspended. Suspended |
| 06 February 2019 | On 1 February 2019, the company (CTI BioPharma) announced that the they will withdraw its European Marketing Authorization Application (MAA) for pacritinib. This is because the company learned from the regulator that it is likely to formally adopt a negative opinion in its evaluation of pacritinib for this indication. Therefore, this appraisal will be suspended. We will continue to monitor any developments and will update stakeholders if the situation changes. |
| 27 November 2018 | Committee meeting: 1 |
| 29 June 2018 | Invitation to participate |
| 10 April 2018 - 09 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 19 May 2017 | The company have advised that they will re-submit a Marketing Authorisation Application in June/July 2017 including a recently completed Phase 3 study (PAC326) “A randomized, Controlled Study of Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Mylofibrosis” and be pursuing a licence for pacritinib from the European Medicines Authority for this indication after the re-submission. Therefore, NICE has decided to suspend this appraisal from its work programme at this point. |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual